It is an autosomal dominant disease whereby the promoter of the chimeric 11β-hydroxylase/aldosterone synthase gene belongs to the 5′ end of CYP11 B1 (11β hydroxylase) and drives the expression of the 3′ end of CYP11 B2 (aldosterone synthase) ectopically in ZF cells under the main regulation by ACTH (69); in these patients, dexamethasone usually decreases aldosterone secretion by more than 80% or to <4 ng/dL (67), but the diagnosis is now performed using genetic analysis. Here, CYP11B2 is linked to autosomal dominant disease.